Trubion Announces Initiation Of Phase IIb Clinical Trial Of TRU-015 For The Treatment Of Rheumatoid Arthritis
Trubion Pharmaceuticals, Inc., today announced it has initiated a Phase IIb clinical trial of TRU-015, the Company’s lead Small Modular ImmunoPharmaceutical (SMIP(TM)) drug candidate for the treatment of rheumatoid arthritis (RA). The randomized, double-blind, placebo-controlled clinical trial is designed to evaluate clinical response rates in patients with rheumatoid arthritis. [click link for full article]

How Central Nervous System Regulates Arthritis
In a unique approach to inflammation research, a study by researchers at the University of California, San Diego (UCSD) School of Medicine shows that, in a model of rheumatoid arthritis, inflammation in the joints can be sensed and modulated by the central nervous system (CNS). The research suggests that the CNS can profoundly influence immune responses, and may even contribute to understanding so-called placebo effects and the role of stress in inflammatory diseases. [click link for full article]

Stanford Study Finds Cancer Drug May Be Remedy For Rheumatoid Arthritis
The potent cancer drug Gleevec, used to combat leukemia and some gastrointestinal cancers, may be useful in treating rheumatoid arthritis, according to a team of researchers at the Stanford University School of Medicine. Their findings will be published in the October issue of the Journal of Clinical Investigation. [click link for full article]